Lianhuan Pharmaceuticals (600513.SH) has obtained the "Drug Registration Certificate" for metoprolol tartrate injection.

Cnfortune APP News, Lianhuang Pharmaceutical (600513.SH) announced that the company recently received the "Drug Registration Certificate" for metaraminol bitartrate injection approved and issued by the National Medical Products Administration (referred to as the "NMPA"). Metaraminol bitartrate injection is used for the control of blood pressure in certain acute hypotensive states (such as chromaffin cell resection surgery, sympathetic nerve resection surgery, spinal poliomyelitis, spinal anesthesia, myocardial infarction, sepsis, transfusion, and drug reactions), as an adjunctive treatment for cardiac arrest and severe hypotension.